JP Patent

JP7094228B2 — Ｎ－［５－（３，５－ジフルオロ－ベンジル）－１ｈ－インダゾール－３－イル］－４－（４－メチル－ピペラジン－１－イル）－２－（テトラヒドロ－ピラン－４－イルアミノ）－ベンズアミドの新規結晶形

Assigned to ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ · Expires 2022-07-01 · 4y expired

What this patent protects

Patent listed against Rozlytrek.

Drugs covered by this patent

Patent Metadata

Patent number
JP7094228B2
Jurisdiction
JP
Classification
—
Expires
2022-07-01
Drug substance claim
No
Drug product claim
No
Assignee
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.